Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany

Coronary heart disease (CHD) remains the leading cause of death in Germany despite statin use to reduce low-density lipoprotein cholesterol (LDL-C) levels; improving lipids beyond LDL-C may further reduce cardiovascular risk. A fixed-dose combination of extended-release niacin (ERN) with laropiprant...

Descripción completa

Detalles Bibliográficos
Autores principales: Michailov, Galin V., Davies, Glenn M., Krobot, Karl J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3343242/
https://www.ncbi.nlm.nih.gov/pubmed/21465286
http://dx.doi.org/10.1007/s10198-011-0309-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3343242/
https://www.ncbi.nlm.nih.gov/pubmed/21465286
http://dx.doi.org/10.1007/s10198-011-0309-z

Ejemplares similares